ThromboGenics Presenting New Ophthalmic Research Data

LEUVEN, Belgium, September 7, 2016 /PRNewswire/ --

ThromboGenics NV (Euronext Brussels: THR), a Belgium-based biopharmaceutical company developing novel medicines for back of the eye disease, with a focus on diabetic eye treatments, announces that the Company will be presenting a wide range of ophthalmic research at the upcoming EURETINA annual Congress held from September 8^th - 11^th 2016 in Copenhagen, Denmark.

EURETINA 2016 will see 15 communications delivering new scientific insights relevant to ThromboGenics development projects, by means of oral presentations, posters and instructional courses. Data will include preclinical and clinical research findings, as well as real-world clinical data, including further characterization of results from ocriplasmin studies such as OASIS and OVIID-I.

OASIS is the acronym for "Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion including Macular Hole". It is a Phase IIIB, randomized, prospective, sham-controlled, double-masked, multicenter clinical study. The goal of the study is to further evaluate the long-term (24 months) efficacy and safety of a single injection of 0.125mg of ocriplasmin in patients with symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT), including macular hole (MH). The full details of the OASIS results have now been published in Ophthalmology, the Journal of the American Academy of Ophthalmology (AAO), and will be presented at EURETINA by Prof Dr Pravin U. Dugel.*

As concluded by the AAO Journal, "the OASIS trial demonstrates the long-term efficacy and safety of ocriplasmin, providing improved resolution of symptomatic VMA compared with previous phase 3 trials with no additional safety signals identified".

Please click here for a complete overview of all presentations and poster delivered at the 16^th Euretina Congress including date and time.

Dr Patrik De Haes, CEO of ThromboGenics nv, comments, "We are pleased to have the opportunity to share our cutting-edge research in the field of diabetic eye disease as well as continue to deliver a vast amount of ocriplasmin data in support of the retina community at this year's EURETINA Congress. The research insights will further grow confidence when considering ocriplasmin as a treatment option in a changing standard of care for the treatment of symptomatic VMA."

- END - 

* Retina Consultants of Arizona, Phoenix, AZ 
  USC Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 

For further information please contact: 

    ThromboGenics                                     Citigate Dewe Rogerson
    Wouter Piepers,                                   David Dible/Sylvie Berrebi
    Global Head of Corporate Communications & IR      Tel: +44 20 7282 9571
    +32 16 75 13 10 / +32 478 33 56 32                david.dible@citigatedr.co.uk
    wouter.piepers@thrombogenics.com                  sylvie.berrebi@citigatedr.co.uk

About ThromboGenics  

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease.

The company's attractive pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market, diabetic retinopathy and diabetic macular edema.

ThromboGenics is conducting a Phase II clinical trial to assess THR-409 (ocriplasmin) as a potential treatment for non-proliferative diabetic retinopathy. THR-317, a neutralizing PIGF mAb being developed for the treatment of diabetic macular edema is expected to enter the clinic by end of 2016.

In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, lead compound from a library of integrin antagonists, in-licensed from Galapagos, are in late stage pre-clinical development.

ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of vitreomacular traction in 54 countries worldwide. ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics, Inc. in the US. Alcon (Novartis) commercializes JETREA® outside the United States.

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.

More information is available at http://www.thrombogenics.com

Important information about forward-looking statements 

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. 

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

SOURCE ThromboGenics